Krystal Biotech Inc is engaged in the healthcare sector in the United States... Show more
The Moving Average Convergence Divergence (MACD) for KRYS turned positive on March 18, 2025. Looking at past instances where KRYS's MACD turned positive, the stock continued to rise in of 60 cases over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on March 11, 2025. You may want to consider a long position or call options on KRYS as a result. In of 108 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
KRYS moved above its 50-day moving average on February 19, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KRYS crossed bullishly above the 50-day moving average on February 21, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where KRYS advanced for three days, in of 308 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 211 cases where KRYS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for KRYS moved out of overbought territory on March 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRYS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
KRYS broke above its upper Bollinger Band on March 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KRYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.695) is normal, around the industry mean (13.948). P/E Ratio (62.367) is within average values for comparable stocks, (66.289). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.930). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (19.157) is also within normal values, averaging (240.137).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a biopharmaceutical company which provides therapies for rare and orphan diseases
Industry Biotechnology
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
LVHD | 40.43 | 0.46 | +1.15% |
Franklin U.S. Low Volatility Hi Div ETF | |||
SRET | 21.20 | 0.06 | +0.28% |
Global X SuperDividend® REIT ETF | |||
IBDT | 25.19 | N/A | N/A |
iShares iBonds Dec 2028 Term Corp ETF | |||
LRND | 33.77 | N/A | N/A |
NYLI U.S. Large Cap R&D Leaders ETF | |||
FGB | 4.31 | -0.01 | -0.33% |
First Trust Specialty Finance and Financial Opportunities Fund |
A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with IDYA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then IDYA could also see price increases.
Ticker / NAME | Correlation To KRYS | 1D Price Change % | ||
---|---|---|---|---|
KRYS | 100% | -2.70% | ||
IDYA - KRYS | 50% Loosely correlated | -3.16% | ||
ACLX - KRYS | 48% Loosely correlated | -2.84% | ||
CRNX - KRYS | 47% Loosely correlated | -1.60% | ||
ZLDPF - KRYS | 45% Loosely correlated | N/A | ||
PRME - KRYS | 45% Loosely correlated | N/A | ||
More |